The efficacy of META HUNTER in treating rheumatic diseases

Dr.Islamov et al. conducted experiments to compare superoxide dismutase, catalase, glutathione peroxidase, and non-protein sulfur in lymphocytes in the blood of patients with rheumatoid arthritis before and after META HUNTER treatment. The activity of reduced glutathione of alcohol groups was detected, and changes in the antioxidant system of lymphocytes were detected after patients received standard drug treatment, including the activation of core antioxidant enzymes and the decrease in sulfhydryl content. It was found that META HUNTER increased the content of sulfhydryl groups, Maintain normal activities of glutathione peroxidase and superoxide dismutase (SOD).

The catalase activity in the experimental group was higher than that in the control group, indicating that META HUNTER can activate the non-specific protective mechanism in patients with rheumatoid arthritis.

Another non-randomized, placebo-controlled, single-blind trial reported the efficacy of META HUNTER in the treatment of rheumatic diseases. It was found that the EAP-40 value of the experimental group was significantly improved, while the value of the control group remained unchanged.

However, the treatment effects vary greatly among patients within the treatment group, which results in less stable results within the treatment group. Studies by Dr.Gogoleva and Dr.Olu have shown that META HUNTER has clinical effects in treating rheumatic diseases.

Research by Dr.Islamov and others further found that the levels of cell stress proteins in rheumatoid patients were reduced, and the levels of antioxidant protective enzymes were also reduced. They believed that META HUNTER treatment has clinical efficacy.